Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114748 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114638 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114552 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114510 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114882 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114879 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114632 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6114943 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL6115138 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 | |
| SCHEMBL15662321 | 1.00 | SPHK1 (0.46) | SPHK1LMNAOPRM1ACE2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821395-A2 | Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery | Wako Pure Chemical Industries, Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8716513-B2 | Process for production of bis-quaternary ammonium salt, and novel intermediate | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2463266-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | ASS1, C1S, FHIT | SPHK1 3824/4885LMNA 4498/4885OPRM1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.